Overall verdict
Neutral
6.0/10
1-year performance
+51.34%
Score breakdown
Up 51.3% over 1 year, 95% of the 52-week range.
Strongest: Growth 9.5/10. Weakest: Shareholder return 0.0/10.
11 analysts, target +0.1% vs the price.
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products.
In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
Sector
Financials
Industry
Insurance
Primary listing
Nyse
United States
CEO
Mark Bertolini
Founded
2012
Employees
2 305
Revenue / employee
5.1M USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- BlackRock, Inc.7.53%
- T. Rowe Price Investment Management, Inc.4.77%
- D. E. Shaw & Co., Inc.4.62%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.03%
- VANGUARD CAPITAL MANAGEMENT LLC3.87%
- AMERICAN CENTURY COMPANIES INC3.31%
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM2.85%
- JANE STREET GROUP, LLC2.33%
- Thrive Capital Management, LLC2.32%
- Other institutions39.58%
- Rest of the register24.78%
403 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
34.48 USD
52-week low
10.69 USD
1-year performance
51.34%
Rising
Year-to-date performance
130.93%
Rising
Drawdown
-3.22%
Near its high
Position in the 52-week range
95% of range
Range: 26.00 USD - 32.16 USD (2 methods agree)
The price implies growth of -28.95% per year; the company grows at 25.00%.
Net margin 3.6%, ROE 34.3%.
Net margin
3.60%
Low
Sector 6.05%|S&P 13.13%
Gross margin
—
Return on equity (ROE)
34.31%
Exceptional
Sector 13.16%|S&P 16.52%
Return on invested capital (ROIC)
27.94%
Free cash flow margin (FCF)
28.59%
Profit-to-cash conversion (FCF conversion)
7.95x
Margin stability
30.1 pts
Very uneven
Revenue to net income
Growth
9.5/10Revenue up 70.4% over 1 year, 90.8% a year over 5.
Revenue (trailing 12 months)
15.3Md USD
Revenue growth (1y)
70.40%
Hyper-growth
Revenue growth (3y)
195.22%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
80.75%
Sharply revised up
Valuation
4.9/10P/E 24.4x, forward P/E 17.7x, PEG 0.11.
P/E (TTM)
24.4x
Expensive
Sector 15.4x|S&P 23.5x
Forward P/E
17.7x
Expensive
EV / EBITDA
—
Sector 53.1x|S&P 14.7x
PEG
0.11
Growth unpriced
Sector 0.29|S&P 0.87
Fair value (reverse DCF)
26.64 USD
Overvalued
Market cap
9.1Md USD
Not scored for a bank or an insurer: its solidity is measured by regulatory capital ratios, which we do not collect.
Net debt / EBITDA
—
Gearing (net debt / equity)
-177.31%
Cash
4.1Md USD
Cash / market cap
44.66%
Cash / total debt
944.24%
Interest coverage
39.7x
Net debt
-3.6Md USD
Equity
2.1Md USD
Closed daily candles, 2 years
Last close on October 9, 2026: 33.37 USD
- MM2031.44
- MM5031.05
- MM20022.37
- RSI 1461.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+7.72%
200-day average slope, 3 months
+22.73%
50-day average slope, 1 month
+1.49%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
2.61 % per day
Volatility change
-33.05%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.89 (7) | 1.91 (8) | 18 732 (10) | 804 (9) | 655 (5) |
| 2027 | 2.15 (7) | 2.17 (8) | 20 795 (10) | 996 (9) | 733 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 6, 2026.
Same sub-industry: 82 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 601318 | 7.4 | N/A | 133Md USD | — | — | 6.5 % | — | — | — | -4.0 % | ||
| 2 | 2628 | 7.3 | 8.5 | 137Md USD | 2.7x | 41.3 % | 36.2 % | — | — | — | -8.9 % | ||
| 3 | GWO | 6.3 | 5.6 | 55.7Md USD | 18.3x | 9.5 % | 21.4 % | — | — | — | 51.9 % | ||
| 4 | MFC | 6.2 | 5.2 | 70.6Md USD | 16.4x | 10.0 % | 28.2 % | — | — | — | 33.2 % | ||
| 5 | OSCR | 6.0 | 5.9 | 9.1Md USD | 24.4x | 3.6 % | 70.4 % | — | — | — | 51.3 % | ||
| 6 | MET | 5.8 | 4.8 | 62.5Md USD | 18.8x | 4.6 % | 11.4 % | — | — | — | 19.6 % | ||
| 7 | 1299 | 5.3 | 5.3 | 93.9Md USD | 11.9x | 23.2 % | 10.0 % | — | — | — | -5.1 % | ||
| 8 | 2881 | 5.3 | 4.5 | 67.0Md USD | 13.1x | 18.1 % | -2.8 % | — | — | — | 75.3 % | ||
| 9 | AFL | 5.1 | 5.4 | 57.4Md USD | 12.3x | 26.9 % | -1.0 % | — | — | — | 1.9 % |
